86506-70-9

Usage

Uses

Used in Oncology:
2-[2-(oxiran-2-yl)ethyl]-1H-isoindole-1,3(2H)-dione is used as a chemotherapeutic agent for the treatment of various forms of cancer, including breast, lung, and bladder cancer. It is particularly effective due to its ability to bind to DNA and disrupt the synthesis of RNA and proteins, leading to the death of cancer cells.
Used in Combination Therapy:
In the field of oncology, 2-[2-(oxiran-2-yl)ethyl]-1H-isoindole-1,3(2H)-dione is used as a component of combination therapy, where it is administered alongside other cancer drugs to enhance the overall effectiveness of treatment and increase the chances of successfully combating the disease.
Used in Cancer Treatment Research:
2-[2-(oxiran-2-yl)ethyl]-1H-isoindole-1,3(2H)-dione is also used as a subject of research in the field of cancer treatment, with ongoing studies aimed at understanding its mechanisms of action, improving its delivery methods, and exploring potential synergistic effects with other therapeutic agents.
Common side effects associated with the use of 2-[2-(oxiran-2-yl)ethyl]-1H-isoindole-1,3(2H)-dione include nausea, vomiting, hair loss, and an increased risk of infection due to its effects on the bone marrow. Despite these side effects, epirubicin remains an important and effective tool in the ongoing fight against cancer.

Upstream product

• 52898-32-5 N-(3-butenyl)phthalimide 
• 1074-82-4 potassium phtalimide 
• 937-14-4 3-chloro-benzenecarboperoxoic acid 
• 136918-14-4 phthalimide 
• 13287-42-8 (2-bromoethyl)oxirane 

Downstream Products

• 402921-65-7 2-(4-{benzyl-[2-(bis-pyridin-2-ylmethylamino)ethyl]amino}-3-hydroxybutyl)phthalimide 
• 944344-35-8 2-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)-3-hydroxybutyl)isoindoline-1,3-dione 
• 944344-36-9 2-(4-(4-(2-methoxyphenyl)piperazin-1-yl)-3-hydroxybutyl)isoindoline-1,3-dione 
• 227776-12-7 2-(4-(4-diphenylmethyl-piperazin-1-yl)-3-hydroxy-butyl]isoindolin-1,3-dione 
• 1301178-76-6 2-(3-fluoro-4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)isoindoline-1,3-dione 
• 1301178-77-7 2-(3-fluoro-4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-isoindoline-1,3-dione 
• 1584155-01-0 (R)-2-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)-3-fluorobutyl)isoindoline-1,3-dione 
• 1584155-00-9 (R)-2-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)-3-hydroxybutyl)isoindoline-1,3-dione 
• 1144854-24-9 2-(3-hydroxy-4-(4-(2-propoxyphenyl)piperazin-1-yl)butyl)isoindoline-1,3-dione 
• 1039747-40-4 C₃₃H₃₆N₄O₃ 

Relevant academic research and scientific papers

Design, synthesis, and biological evaluation of 2-(benzylamino-2-hydroxyalkyl)isoindoline-1,3-diones derivatives as potential disease-modifying multifunctional anti-Alzheimer agents

The complex nature of Alzheimer's disease calls for multidirectional treatment. Consequently, the search for multi-target-directed ligands may lead to potential drug candidates. The aim of the present study is to seek multifunctional compounds with expected activity against disease-modifying and symptomatic targets. A series of 15 drug-like various substituted derivatives of 2-(benzylamino-2-hydroxyalkyl)isoindoline-1,3-diones was designed by modification of cholinesterase inhibitors toward β-secretase inhibition. All target compounds have been synthesized and tested against eel acetylcholinesterase (eeAChE), equine serum butyrylcholinesterase (eqBuChE), human β-secretase (hBACE-1), and β-amyloid (Aβ-aggregation). The most promising compound, 12 (2-(5-(benzylamino)-4-hydroxypentyl)isoindoline-1,3-dione), displayed inhibitory potency against eeAChE (IC50 = 3.33 μM), hBACE-1 (43.7% at 50 μM), and Aβ-aggregation (24.9% at 10 μM). Molecular modeling studies have revealed possible interaction of compound 12 with the active sites of both enzymes-acetylcholinesterase and β-secretase. In conclusion: modifications of acetylcholinesterase inhibitors led to the discovery of a multipotent anti-Alzheimer's agent, with moderate and balanced potency, capable of inhibiting acetylcholinesterase, a symptomatic target, and disease-modifying targets: β-secretase and Aβ-aggregation.

TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS

A compound of formula (I) wherein: R1 is optionally one or more halo or methyl groups; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2c and R2d are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R3a and R3b are independently selected from H and Me; R4 is either H or Me; R5 is either H or Me; A is either (i) optionally substituted phenyl; (ii) optionally substituted naphthyl; or (iii) optionally substituted C5-12 heteroaryl.

High Affinity Dopamine D3 Receptor (D3R)-Selective Antagonists Attenuate Heroin Self-Administration in Wild-Type but not D3R Knockout Mice

The dopamine D3 receptor (D3R) is a promising target for the development of pharmacotherapeutics to treat substance use disorders. Several D3R-selective antagonists are effective in animal models of drug abuse, especially

PHENYL CARBAMATES AND THEIR USE AS INHIBITORS OF THE FATTY ACID AMIDE HYDROLASE (FAAH) ENZYME AND MODULATORS OF THE D3 DOPAMINE RECEPTOR (D3DR)

The invention provides compounds of Formula (I) or pharmaceutically acceptable salts thereof wherein Ar', R1, R2, R3, R4, X, Y are as defined in the description of invention, as multi-target directed ligands (MT

Synthesis and evaluation of fluoro substituted pyridinylcarboxamides and their phenylazo analogues for potential dopamine D3 receptor PET imaging

A series of fluoro substituted pyridinylcarboxamides and their phenylazo analogues with high affinity and selectivity for the dopamine D3 receptor was synthesized by the use of 6-fluoropyridine-3-carbonyl chloride (1) and fluorophenylazocarboxylic ester (

Chiral resolution and serendipitous fluorination reaction for the selective dopamine d3 receptor antagonist BAK2-66

The improved chiral synthesis of the selective dopamine D3 receptor (D3R) antagonist (R)-N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)-3-hydroxybutyl)1H- indole-2-carboxamide ((R)-PG648) is described. The same chiral secondary alcohol intermediate was used to prepare the enantiomers of a 3-F-benzofuranyl analogue, BAK 2-66. The absolute configurations of the 3-F enantiomers were assigned from their X-ray crystal structures that confirmed retention of configuration during fluorination with N,N-diethylaminosulfur trifluoride (DAST). (R)-BAK2-66 showed higher D3R affinity and selectivity than its (S)-enantiomer; however, it had lower D3R affinity and enantioselectivity than (R)-PG648. Further, importance of the 4-atom linker length between the aryl amide and 4-phenylpiperazine was demonstrated with the 4-fluorobutyl-product (8). This article not subject to U.S. Copyright. Published 2014 by the American Chemical Society.

ARYLPIPERAZINE-CONTAINING PURINE DERIVATIVES AND USES THEREOF

A novel arylpiperazine-containing purine derivatives and a pharmaceutical composition comprising the same as an active ingredient, which are useful for preventing or treating depressive disorders, are provided.

4-PHENYLPIPERAZINE DERIVATIVES WITH FUNCTIONALIZED LINKERS AS DOPAMINE D3 RECEPTOR SELECTIVE LIGANDS AND METHODS OF USE

Dopamine D3 receptor antagonists and partial agonists are known to modulate the reinforcing and drug-seeking effects induced by cocaine and other abused substances. By introducing functionality into the butylamide linking chain of the 4-phenylp

4-PHENYLPIPERAZINE DERIVATIVES WITH FUNCTIONALIZED LINKERS AS DOPAMINE D3 RECEPTOR SELECTIVE LIGANDS AND METHODS OF USE

Dopamine D3 receptor antagonists and partial agonists are known to modulate the reinforcing and drug-seeking effects induced by cocaine and other abused substances. By introducing functionality into the butylamide linking chain of the 4-phenylp

Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl) arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: Potential substance abuse therapeutic agents

Dopamine D3 receptor antagonists and partial agonists have been shown to modulate drug-seeking effects induced by cocaine and other abused substances. Compound 6 [PG01037, (N-(4-(4-(2,3-dichlorophenyl)-piperazin-1-yl)-trans-but-2- enyl)-4-pyridine-2-ylben